Expanded Options for Cancer Researchers with Leica Biosystems and Advanced Cell Diagnostics Automated RNA ISH Workflow with Powerful Aperio Image Analysis*
VISTA, California, November 30, 2016 /PRNewswire/ --
* Aperio RNA ISH Algorithm and BOND RX are for Research Use Only. Not for use in diagnostic procedures.
Leica Biosystems and Advanced Cell Diagnostics (ACD) - a Bio-Techne brand, proudly announce the availability of the Aperio RNA ISH Algorithm for use with ACD's RNAscope ISH assays.
(Photo: http://photos.prnewswire.com/prnh/20161130/444037 )
This offering builds on the existing collaboration between the two companies to automate ACD's RNAscope assays on the Leica Biosystems BOND RX research staining platform. The Leica Biosystems new RNA ISH Algorithm completes the automated RNA ISH workflow for researchers performing the RNAscope assay on the BOND RX.
RNA in-situ hybridization (ISH) is a powerful molecular technique. ACD's RNAscope assays provide robust single RNA molecule detection for formalin-fixed, paraffin-embedded (FFPE) tissue. These assays have been adopted across the globe by major pharma biotech companies, and leading research institutions at more than 3000 labs.
However, manual RNA ISH interpretation is time-consuming, subject to inter- and intra-observer variability, and typically only semi-quantitative. The Aperio RNA ISH Algorithm enables accurate identification and standardized quantification of individual signals and clusters on single- or dual-plex stained slides. Now, researchers using the Leica Biosystems BOND RX can seamlessly generate quantitative results using the Aperio image analysis software.
"The new Aperio RNA ISH Algorithm from our innovation partner, Leica Biosystems, is a welcome addition to our RNAscope data analysis tool set, providing expanded options for our customers pursuing diverse analyses in academic research, drug development and clinical research, said Chris Silva, Vice President of Marketing at ACD. "With our expanding list of applications in immune-oncology, inflammation, neuroscience and infectious disease, flexibility in generating various quantitative analysis further enables our customers to make enhanced interpretation of what is visualized."
Marlon Thompson, Vice President, Image Analysis and Clinical Solutions at Leica Biosystems added, "Leica Biosystems is excited to expand on the existing partnership with ACD by providing high-end image analysis capabilities that complements a complete solution from assay to results. Customers can leverage an automated assay and the underlying power of digital pathology to more easily attain accurate, standardized and reproducible results."
Learn more about the ACD and LBS solution for RNA ISH in the upcoming live webinar on Dec 1st 2016: "RNA ISH - Automated Solutions for Better Research." Register here.
Media Contact(s): Kristin O'Neill, Manager, Global Brand Marketing LBS-GlobalMarketing@leicabiosystems.com +1-847-821-3537
SOURCE Leica Biosystems